Group 1 - The European Medicines Agency has recommended granting marketing authorization for Moderna's mCombriax, making it the first combined vaccine for COVID-19 and seasonal influenza for individuals aged 50 and older [1] - The vaccine utilizes messenger RNA technology, which has been pivotal in the development of COVID-19 vaccines [1] Group 2 - The approval of mCombriax represents a significant advancement in public health, potentially simplifying vaccination processes for older populations [1] - This development may enhance Moderna's market position and revenue potential in the vaccine sector [1]

​Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the Best All-Time Low Stocks to Invest In Now. On February 24, Caris Life Sciences, Inc. (NASDAQ:CAI) announced that it is adding a new AI-powered “breast cancer signature” to its Caris Molecular Tumor Board Report. The report is a research tool that doctors and researchers use for additional tumor biology resources and can be ordered with the company’s MI Cancer Seek. ​Management noted that the report will now include a “Caris AI Insights” section with s ...

Core Viewpoint - Corcept Therapeutics Incorporated is facing a class action lawsuit for alleged violations of securities laws, specifically for making false and misleading statements regarding its product candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Corcept misled investors by stating that relacorilant was "approaching approval" despite receiving warnings from the FDA about insufficient clinical data [1]. - The deadline for shareholders to participate in the lawsuit is April 21, 2026 [1]. - The class action is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. Group 2: Company Background - Corcept Therapeutics is publicly traded on NASDAQ under the ticker symbol CORT [1]. - The company is accused of making materially misleading public statements throughout the class period, which could have significant implications for its stock value and investor trust [1].

In this article, we talk about the 15 stocks with the biggest hedge fund momentum.On February 23, Bloomberg News reported that during the week ended February 19, hedge funds registered record-high net sales of global stocks, the highest since early April 2025. Despite the selling spree, hedge funds maintained solid performance in early 2026, a period characterized by choppy markets and including the worst single-day drop for three major fund strategies since the COVID-19 pandemic.Goldman Sachs Group Inc.’s ...

Grail Inc. (NASDAQ:GRAL) is one of the best small-cap stocks with huge growth potential. On February 20, Baird cut the price target on Grail Inc. (NASDAQ:GRAL) to $82 from $113 while maintaining an Outperform rating on the shares. The rating update came after the announcement that its NHS study missed its primary endpoint. 15 Healthiest Countries In Africa A healthcare professional wearing a health communications device discussing patient data with a colleague. The same day, Canaccord also cut the price ...

Core Insights - The presentation focuses on pivotal updates regarding the MissionEB Phase III clinical trial and the impact of CORDStrom on Recessive Dystrophic Epidermolysis Bullosa (RDEB) [1] Group 1: Company Overview - David Moss serves as the President, CEO, Treasurer, Secretary, and Director of INmune Bio, highlighting the company's leadership structure [1] - The event is being recorded and will be available on the company's YouTube channel later, indicating a commitment to transparency and communication with stakeholders [2] Group 2: Key Personnel - Dr. Mark Lowdell is introduced as the inventor of CORDStrom and a pioneer in cellular therapy, emphasizing his significant contributions to the development of advanced medicinal products [3] - Dr. Anna Martinez is the clinical lead for the MissionEB trial and a leading expert in the field of Epidermolysis Bullosa, showcasing the expertise driving the clinical program [4]

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best strong buy healthcare stocks to invest in. Revolution Medicines, Inc. (NASDAQ:RVMD) was initiated with an Outperform rating and a $140 price target by Evercore ISI on February 25. The firm set a $140 price target on the stock, stating that with the expected launch of daraxonrasib, the company is “poised for a potential breakthrough in oncology”. With strategic distractions fading, Evercore sees “a promising entry point” ahead of key Phase 3 data i ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the upcoming lead plaintiff deadline on April 13, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - To serve as lead plaintiff, individuals must file with the court by April 13, 2026, acting on behalf of other class members [3]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study for a drug candidate aimed at Huntington's Disease, including FDA approval status and the potential delay in its Biologics License Application (BLA) timeline [5]. - The defendants allegedly downplayed the likelihood of needing additional studies, which led to misleading statements about uniQure's business and prospects [5]. - The lawsuit claims that when the true details became known, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Company Overview - Generate Biomedicines has successfully raised $400 million through its U.S. initial public offering (IPO) by pricing shares at $16 each [1]. Financial Highlights - The IPO raised a total of $400 million, indicating strong investor interest in the company's drug development capabilities [1].

Record Q4 revenue growth of 23% was primarily volume-driven, supported by the highest number of MACI implants and implanting surgeons since the product's 2017 launch. The MACI Arthro technique has successfully accelerated growth in the small condyle defect segment, which historically lagged but became a top growth driver in 2025. Surgeons trained in MACI Arthro demonstrate higher biopsy and implant growth rates, with even higher conversion rates observed once they complete their first Arthro case. M ...